| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $16.1M | — |
| Cost of Revenue | $475K | — |
| R&D Expense | $58.7M | +18.5% |
| SG&A Expense | $25.4M | -22.0% |
| Operating Income | -$89.5M | -8.8% |
| Pre-tax Income | -$79.5M | -7.7% |
| Income Tax | -$2.2M | — |
| Net Income | -$77.3M | -4.8% |
| EPS (Basic) | -$1.32 |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $19.5M | +101.5% |
| Short-term Investments | $107.5M | -2.0% |
| Current Assets | $132.4M | +6.3% |
| Total Assets | $157.2M | -9.5% |
| Current Liabilities | $17.7M | -31.4% |
| Total Liabilities | $36.4M | -24.1% |
| Stockholders' Equity | $120.8M | -3.9% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$57.7M | +18.4% |
| Capital Expenditures | $237K | -96.5% |
| Investing Cash Flow | $8.2M | +107.8% |
| Financing Cash Flow | $59.3M | +900.6% |
| Free Cash Flow | -$57.9M | +25.2% |
| EPS (Diluted) | -$1.32 | +28.6% |